Neurocrine Bioscience Stock
€135.75
Your prediction
Neurocrine Bioscience Stock
Pros and Cons of Neurocrine Bioscience in the next few years
Pros
Cons
Performance of Neurocrine Bioscience vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Neurocrine Bioscience | 0.110% | 0.593% | 20.828% | 24.427% | 11.225% | 59.668% | 72.754% |
| Ligand Pharmaceuticals | -2.940% | 7.447% | 1.508% | 126.966% | 21.687% | 190.647% | 109.848% |
| United Therapeutics | -1.000% | -0.863% | -0.720% | 72.825% | 12.965% | 143.788% | 215.490% |
| Ionis Pharmaceuticals Inc. | 0.780% | 3.081% | 2.341% | 122.758% | -3.502% | 72.171% | 114.664% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Neurocrine Biosciences (NASDAQ: NBIX), a company operating in the Biotechnology & Medical Research industry, showcases an interesting financial outlook. The company's financials indicate a growing revenue base and a healthy mix of both current and non-current assets. However, there are also aspects where the company could potentially face challenges, warranting a deeper analysis of its financial standing.
Growing Revenue: Neurocrine has consistently increased its revenue over the past three years, with total revenues of $1.05 billion in 2020, $1.13 billion in 2021, and $1.49 billion in 2022. This reflects a strong demand for the company's products and services.
Increasing Gross Profit: The gross profit has seen a continuous upward trend with $1.04 billion in 2020, $1.12 billion in 2021, and $1.47 billion in 2022. This suggests that the company is efficiently managing its cost of revenue, enabling higher profitability.
Comments
News
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference
Key Points
- Interested in Ionis Pharmaceuticals, Inc.? Here are five stocks we like better.
- Ionis Pharmaceuticals said TRYNGOLZA could become a more than $3 billion U.S. product in severe
Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout Agreement
Soleno Therapeutics (NASDAQ:SLNO), a rare-disease drug developer, closed Monday at $52.26, up 32.31%. The stock’s move reflects Neurocrine Biosciences’ (NASDAQ:NBIX) $53-per-share all-cash
Why Soleno Therapeutics Stock Rocketed Higher on Monday
On news that Soleno Therapeutics (NASDAQ: SLNO) has agreed to be acquired, investors piled into the company's shares on Monday. This left the commercial-stage biotech with a juicy 32% gain on the